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PENJANAAN DAN PENCIRIAN APTAMER RNA TERHADAP PROTEIN 
ESAT6 DARIPADA MYCOBACTERIUM TUBERCULOSIS  
 
ABSTRAK 
 
Aptamer adalah ligan kimia terbina daripada jujukan nukleotida pendek yang 
berkemampuan untuk berinteraksi dengan protein pada kadar afiniti dan ketentuan 
yang tinggi. Aptamer dihasilkan melalui suatu process yang dinamakan Evolusi Ligan 
Secara Sistemik melalui Pengkayaan Eksponen (Systematic Evolution of Ligands via 
Exponential Enrichment) atau secara ringkasnya, SELEX. Oleh kerana kadar 
kestabilan struktur and ketentuan yang tinggi di antara aptamer dengan protein 
sasarannya, aptamer mempunyai potensi yang amat tinggi untuk menjadi alatan 
biologi molekul yang berguna. Early Secretory Antigenic Target (ESAT6), ialah 
sejenis protein dengan jisim molekul 6 kDa yang dihasilkan oleh Mycobacterium 
tuberculosis dan dipercayai mempunyai peranan yang penting dalam penyebaran dan 
perkembangan penyakit tuberkulosis (TB). Protein ini terletak pada lokus yang 
dikenali sebagai Region of Difference 1 (RD1) di dalam genom Mycobacterium sp. 
dan kehilangan lokus ini menyebabkan bakteria tersebut tidak dapat untuk menjangkiti 
hos. Berdasarkan bukti tersebut, ESAT6 adalah berpotensi untuk menjadi penanda 
biologi untuk penyakit TB. Dengan itu, penjanaan aptamer terhadap molekul ini dapat 
menjadi satu batu loncatan untuk penghasilan ujian diagnosis TB yang dapat 
menjimatkan masa, wang dan sebagai kegunaan terapeutik. Matlamat kajian ini adalah 
untuk menghasilkan aptamer RNA yang boleh berinteraksi dengan ESAT6 secara 
khusus dan afiniti yang tinggi. Sebelas kitaran SELEX telah dijalankan menggunakan 
koleksi helaian tunggal RNA rawak. Ketegaran interaksi di antara jujukan RNA dan 
 xvi 
 
ESAT6 dinaikkan secara beransur-ansur dengan mengubah jumlah protein, koleksi 
jujukan RNA dan pesaing dengan setiap kitaran SELEX. Koleksi RNA yang terhasil 
pada kitaran SELEX ke 11 dikaji selanjutnya dengan cerakin nitrocellulose filter 
binding dan afiniti terhadap ESAT6 telah dinilai. Berdasarkan keputusan cerakin 
nitrocellulose filter binding, pengkayaan koleksi jujukan RNA telah disahkan berlaku. 
Cerakin tersebut juga mempostulatkan bahawa terdapat calon-calon aptamer di dalam 
koleksi RNA kitaran SELEX ke 8 dan 11. Analisis jujukan populasi RNA pada koleksi 
RNA kitaran ke 8 dan 11 menunjukkan kehadiran beberapa jenis jujukan RNA yang 
dapat dinobatkan sebagai calon aptamer terhadap ESAT6. Kajian selanjutnya telah 
mengenal pasti dua spesis aptamer, dinamakan RAE6-1 dan RAE6-3, yang 
mempunyai afiniti terbaik terhadap ESAT6. Dengan menggunakan lengkuk regresi 
bukan linear, kadar penceraian, Kd, telah ditentukan sebagai 595.8 nM untuk RAE6-1, 
dan 561.9 nM bagi RAE6-3. Maklumat jujukan sepsis aptamer ini digunakan untuk 
penjangkaan struktur sekundernya. Jujukan kedua-dua aptamer ini setersunya 
disunting untuk memendekkan saiz tanpa mengubah struktur utama aptamer tersebut. 
Dengan menggunakan kaedah pemotongan langkah demi langkah, sebanyak 10 
nukleotida dapat disunting keluar untuk aptamer RAE6-1, memendekkan aptamer 
tersebut dari 80 ke 70 nukleotida. Bagi aptamer RAE6-3, 8 nukleotida dapat disunting 
keluar, memendekkan saiz aptamer tersebut dari 80 ke 72 nukleotida. Secara 
kesimpulannya, dua aptamer RNA, RAE6-1 dan RAE6-3, telah berjaya dihasilkan 
melalui proses SELEX dan pencirian aptamer-aptamer tersebut juga telah dijalankan.  
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GENERATION AND CHARACTERISATION OF RNA APTAMERS 
AGAINST ESAT6 PROTEIN FROM MYCOBACTERIUM TUBERCULOSIS  
 
ABSTRACT 
 
Aptamers are chemical ligands made up of short nucleotides sequences that are 
able to bind to target proteins with high affinity and specificity. They are generated 
using a process called Systemic Evolution of Ligands via Exponential Enrichment 
(SELEX). Due to their chemical stability and high specificity against the target, 
aptamers have the potential to become very useful biological tools. The 6 kDa Early 
Secretory Antigenic Target, or ESAT6, is a secretory protein produced by 
Mycobacterium tuberculosis and is thought to be a major player in mycobacterial 
pathogenesis. The protein is found on a locus known as Region of Difference 1 (RD1) 
and the loss of this locus has been shown to render the Mycobacterium sp. unable to 
cause severe TB. Following this line of evidence, ESAT6 could potentially be a good 
biomarker for TB infection. As such, producing an aptamer against this protein could 
prove valuable in the attempt to create a novel and economical TB diagnostic assay 
with the potential in treating the disease. The objective of this study is to generate RNA 
aptamers that can bind specifically and with high affinity to ESAT6 protein. Eleven 
SELEX cycles were carried out using the N40-randomised RNA pool. Stringency of 
the binding reaction in each SELEX cycles was increased gradually by varying the 
amounts of protein, RNA pool and the competitor. The resulting RNA pool from the 
8th and 11th cycle of SELEX was subjected to filter binding assay to assess its binding 
against ESAT-6 protein. Filter binding assay against the target protein confirmed that 
binding enrichment of the RNA pool has indeed occurred. Nitrocellulose Filter 
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Membrane Binding assay suggested the presence of potential binders in the RNA pool. 
Sequence analyses revealed that different species of potential candidate aptamers were 
present in both the 8th and 11th cycle pool. Further investigations with the binding assay 
identified aptamer species, RAE6-1 and RAE6-3 as having the best affinity towards 
ESAT6. Using a non-linear regression curve, the dissociation constant, Kd, of the 
aptamers were determined to be 595.8 and 561.9 nM for RAE6-1 and RAE6-3, 
respectively. The aptamers were then truncated to reduce them to the shortest possible 
length without compromising the main secondary structures. A total of 10 nucleotides 
were able to be excised from RAE6-1, shortening its length from 80 to 70 nucleotides. 
Meanwhile, 8 nucleotides were removed from RAE6-3, making the aptamer shorter 
from 80 to 72 nucleotides long. In conclusion, two RNA aptamers, RAE6-1 and RAE6-
3, have been successfully generated using the SELEX method and the aptamers were 
characterised. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Aptamer 
 
Aptamers are short, single stranded sequences of DNA or RNA with high specificity 
and affinity to their targets. The name itself is a portmanteau, derived from the Latin 
word ‘aptus’, meaning ‘to fit’ and the Greek word ‘meros’, meaning ‘part’ (Ellington 
& Szostak, 1990), alluding to the stereochemical nature of these molecules which 
grants them binding capabilities to their targets. The term itself was first used by 
Ellington and Szostak in their seminal paper in 1990. The specificity and affinity of 
aptamers towards their target molecules meant that they are sometimes also called 
chemical or synthetic antibodies.  
 
Aptamers form secondary structures as a result of intramolecular base pairing, 
which allows them to interact with the molecular structures and functional groups of 
their target proteins (Kim & Gu, 2013). The resulting conformation will interact with 
its target via shape complementarity, hydrogen bonding, electrostatic attraction and 
stacking (Hermann & Patel, 2000; Patel, 1997). 
 
Aptamers have tremendous potential to be very useful biological tools and 
should be developed and investigated further for uses in diagnostic and therapeutic 
fields. 
 
 2 
 
1.1.1 A Brief History of Aptamer & SELEX  
 
Two research groups from America, Tuerk and Gold, 1990, and Ellington and Szostak, 
1990, independently developed an in vitro method to select RNA molecule against 
specific target proteins. Interestingly, and as typically happens in science, both of these 
groups did not set out to outright create a synthetic affinity reagent. In fact, in Tuerk 
and Gold’s case, the study that lead to the development of this methodology is an 
extension of their previous research on bacteriophage T4 DNA polymerase 
interactions with its own mRNA (Tuerk & Gold, 1990).  
 
Ellington and Szostak on the other hand was intrigued by the idea of active 
binding sites that could have spontaneously arisen from a collection of random 
sequence of nucleotides and what that would mean for theories on the origin and 
evolution of life (Ellington & Szostak, 1990). Nonetheless, both groups are now 
widely regarded as pioneers in the field of aptamers and responsible for coming up 
with the process of developing and selecting aptamers from a randomised pool of 
nucleotides. 
 
This method, dubbed Systematic Evolution of Ligand via Exponential 
Enrichment or SELEX by Tuerk and Gold, involves single stranded DNA or RNA 
library being incubated with a target protein, followed by partitioning to remove the 
unbound from the target-bound sequences (Tuerk & Gold, 1990). A simplified 
representation of the whole process is provided in Figure 1.1. The bound sequences 
are collected and amplified using polymerase chain reaction (PCR) to increase their 
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population within the sequence library. In the case of DNA aptamer generation, the 
double stranded DNA (dsDNA) has to be converted into single stranded DNA 
(ssDNA). RNA aptamer generation on the other hand involves an in vitro transcription 
step to convert the dsDNA into RNA. The cycle of incubation, partitioning and 
amplification is repeated for a few more times until the pool of RNA or DNA is 
populated with high specificity and affinity aptamer candidates (Gopinath, 2011). 
 
Competing reagents and counter selection steps would typically be included in 
the SELEX assay with additional cycles to induce a higher selective pressure for the 
isolation of high specificity and affinity aptamer. As the term “evolution” in the name 
SELEX suggests, sequences that can bind to the target protein will continue to 
proliferate throughout the generations within the pool while the ones that do not will 
be removed. Following this iterative cycle of incubation with target protein, separation 
of bound from unbound species, and sequence amplification over the course of the 
experiment, a nucleic acid pool containing enriched potential aptamer sequences that 
are able to strongly bind to the intended target protein will be obtained.
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Figure 1.1 - A simplified SELEX diagram. Initial single stranded DNA/RNA pool (A) is incubated with protein of interest (B) and a 
partitioning step is performed to separate and remove unbound sequences from the population (C). The bound sequences will be 
recovered (D) and subsequently amplified using PCR. RT-PCR is necessary prior to PCR for RNA sequences (E). The pool will be 
converted back to either ssDNA or ssRNA before starting a new SELEX cycle (F). After 8-15 cycles, candidate aptamers can be 
identified for further analyses (G).
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1.1.2 Advantages of Aptamers 
 
While fulfilling the same niche, aptamers possess a number of advantages over the 
more established antibodies. Since they are chemically synthesised, aptamers are much 
more economical to produce compared to antibodies (Low, Hill, & Peccia, 2009; Sun 
& Zu, 2015). A recent study in 2015 estimated that an aptamer based flow cytometric 
assay is 1000 times cheaper compared to its antibody counterpart (Sun, Tan, & Zu, 
2015). Moreover, as aptamers can be synthesised without a biological host, their 
development can be done faster and with no batch to batch variation problems as 
typically seen in polyclonal antibody productions (Jayasena, 1999; Marx, 2013; 
Wiberg et al., 2006). When an aptamer has been identified, the sequence can be 
reproduced consistently and with high fidelity each time. The fact that they do not need 
to be raised in a biological host also means that aptamers for toxic molecules can also 
be developed in the lab (Rozenblum, Lopez, Vitullo, & Radrizzani, 2016). 
 
Compared to antibodies, aptamers are much smaller in size. A 100 bp RNA 
aptamer for instance is about 32 kDa which is much lighter compared to an 
immunoglobulin monomer, estimated at about 150 kDa (Ma & O’Kennedy, 2015; Sun 
et al., 2014). This size difference permits aptamers to penetrate tissue and cells much 
more easily to bind to their target molecules, suggesting that it could be a more 
sensitive reporter molecule (Jayasena, 1999). This would also mean that aptamers 
developed for therapeutic purposes have a much high clearance rate from the host or 
patients system (Hicke & Stephens, 2000). 
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Aptamers are also more thermodynamically stable compared to antibodies 
(Huang, Xi, & He, 2015; Ospina-Villa, Zamorano-Carrillo, Castañón-Sánchez, 
Ramírez-Moreno, & Marchat, 2016). When exposed to high temperature, they undergo 
reversible denaturation and are able to form their original structures upon renaturation 
(Jayasena, 1999; SantaLucia & Hicks, 2004). 
 
Moreover, aptamers can be tailor-made to suit the intended downstream usage 
planned for them. For instance, an aptamer intended to be used in a diagnostic test can 
be selected at room temperature (RT) while one that is developed to be used for 
therapeutic purposes can be selected at 37oC. Besides temperature, other parameters 
such as medium conditions can be integrated into the SELEX method as well. This is 
in contrast to antibodies which are traditionally raised in a biological host with a body 
temperature of 37oC, which is later adopted to work in varying lab conditions 
(Jayasena, 1999; Stoltenburg, Reinemann, & Strehlitz, 2007). 
 
Aptamers are less immunogenic compared to antibodies (Bouchard, Hutabarat, & 
Thompson, 2010; Cload, McCauley, Keefe, Healy, & Wilson, 2006; Mori, Oguro, 
Ohtsu, & Nakamura, 2004). This is a desirable feature to have in diagnostic assays and 
especially therapeutic purposes as unintended interactions with other immunoreactive 
molecules could lead to the trigger of immune system and inadvertent adverse 
physiological side effects. 
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Aptamers can also be easily modified through various chemical processes that 
could imbue them with various useful properties, increasing their utility in research, 
diagnostics and therapeutic applications. For instance, substitution at the 2’ position of 
ribose on the nucleic acid backbone from hydroxyl (-OH) functional groups to amino 
(-NH2), fluoro (-F) or methoxy (-OCH3) groups confers the aptamer with an improved 
nuclease resistance (Zhang, 2015). Locked nucleic acid (LNA) is another type of 
modification that gives aptamers increased nuclear resistance and thermal stability. In 
LNA, a methyl bridge is introduced between the 2’ oxygen and 4’ carbon of the ribose 
group (Koshkin et al., 1998). With this modification, the aptamer will no longer be a 
substrate for nucleases and will help improve survivability and stability in nuclease-
rich environments (Schmidt et al., 2004; Zhang, 2015). SOMAmers, or Slow Off-rate 
Modified Aptamers, are a new type of aptamers developed by the research group of 
Larry Gold, an aptamer pioneer. SOMAmers, incorporate modified nucleotides with 
side chains that confer more protein-like properties to the aptamer (Gold et al., 2010; 
Rohloff et al., 2014). The side chains on the nucleotides used in the selection process 
are thought to be helpful in developing aptamers with sub-nanomolar dissociation 
constants, give them useful properties such as nuclease resistance, increased stability, 
improve binding ability, attachment to beads or surfaces, and as signalling purposes 
(Gupta et al., 2011; Rohloff et al., 2014; Zhang, 2015). 
 
There have been many studies demonstrating the high applicability of 
aptamers-based diagnosis in actual diagnostic conditions, no doubt due to the many 
advantages conferred by aptamers (LaVan, McGuire, & Langer, 2003; Liu, 
Mazumdar, & Lu, 2006; Mok & Li, 2008). These findings are certainly welcome and 
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support the effort to promote and advertise the untapped potentials of aptamer in the 
many fields of biology. 
 
1.2 Tuberculosis and Mycobacterium tuberculosis 
 
Tuberculosis (TB) is one the most devastating infectious disease known to man. The 
World Health Organisation (WHO) estimated that 10.4 million people worldwide in 
2015 suffered from the disease caused by Mycobacterium tuberculosis (Mtb). Closer 
to home, the Global WHO report also estimated that Malaysia saw 27,000 incidences 
of TB in the year 2015 (WHO, 2016). The ease and increasing movements of people 
in and out of national borders within the South-East Asian region especially from high 
tuberculosis burden countries such as Thailand and Vietnam has been suggested by Dr 
Chong Chee Keong, the Malaysian Ministry of Health (MOH) director of disease 
control division, as one of the factors in the surge of TB cases over the last 20 years 
(Ng Benedict, 2014). In the effort to manage the disease and patients suffering from 
it, the MOH has announced that a National Tuberculosis Strategic Plan for 2016-2020 
is in the process of being prepared and implemented (Roslan, 2016). 
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1.2.1 ESAT6 
 
M. tuberculosis has the ability to bypass hosts’ immune system using complex 
strategies. One such tactic is by releasing a protein called Early Secretory Antigenic 
Target 6 (ESAT6) into its environment in the course of infection. ESAT6 is a 6 kDa 
protein made up of 95 amino acid residues forming two alpha helices motifs connected 
by a loop (Figure 1.2) (Poulsen, Panjikar, Holton, Wilmanns, & Song, 2014; Renshaw 
et al., 2005). 
  
 10 
 
(a)  
(b)  
Figure 1.2 – Structural representation of ESAT6. (a) ESAT6 structure is comprised of 
2 alpha helices connected by a loop. (b) ESAT6-CFP10 heterodimer. Protein models 
generated using Phyre2 protein folding prediction tool 
(http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) and RCSB Protein Data 
Bank (http://www.rcsb.org/pdb/ngl/ngl.do?pdbid=1WA8).   
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It forms a 1:1 heterodimer complex with a neighbouring gene product called 
CFP10 (culture filtrate protein, 10 kDa) thus giving them structural stability when 
released into the environment, and is released via the ESX1 type VII secretion system 
(Abdallah et al., 2007; Lightbody et al., 2008; Renshaw et al., 2005). This is supported 
by the fact that both ESAT6 as well as CFP10 are part of the WXG100 protein 
superfamily, noted for its predisposition to form either homo- or heterodimeric 
complexes from mono-cistronic gene or bi-cistronic genes, respectively (Pallen, 2002; 
Poulsen et al., 2014). 
 
Previous studies have shown that ESAT6 is a potent T-cell antigen, strongly 
eliciting the production of interferon-gamma (IFN-γ) as an immune response (Cardoso 
et al., 2002; Marei et al., 2005; Simeone, Bottai, & Brosch, 2009; van Pinxteren, Ravn, 
Agger, Pollock, & Andersen, 2000). The secreted protein has been also shown to 
confer protection to the invading pathogens against host immune system and even 
allowed them to spread the infection even further (Peng & Sun, 2016). 
 
1.2.2 Role of ESAT6 in Pathogenesis 
 
M. tuberculosis survives in its host’s environment through sophisticated strategies 
involving ESAT6. Studies have shown that the bacterium relies on the secretion of 
ESAT6 to escape the phagosomal membrane of macrophage and dendritic cells and 
enter into the cytosol (van der Wel et al., 2007). Other studies have suggested that 
secreted ESAT6 promotes apoptosis of the cell when the bacterium is internalised by 
macrophages (Derrick & Morris, 2007; Welin, Eklund, Stendahl, & Lerm, 2011). 
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While it has been noted that ESAT6 forms a tight 1:1 with CFP10, the acidic 
environment of phagosomal membrane triggers the detachment of ESAT6 from the 
ESAT6-CFP10 heterodimer, leading to the disruption of lipid bilayer by ESAT6 and 
pore formation on the membrane, allowing the mycobacterial cells to escape cytolysis 
(de Jonge et al., 2007).  
 
Using Mycobacterium marinum as a model, it was reported that further release 
of ESAT6-CFP10 into the extracellular space allows for the interaction between the 
heterodimer molecule and neighbouring epithelial cells, which then induces 
inflammatory matrix metalloprotease 9 (MMP-9) response in the latter (Volkman et 
al., 2010). This results in the recruitment of even more macrophages and granuloma 
expansion to the area thus allowing the invading mycobacteria to infect more 
macrophages (Boggaram, Gottipati, Wang, & Samten, 2013; Volkman et al., 2010). 
 
In a recent study, ESAT6 also has been shown to have the ability to affect 
macrophage ability to present antigens. It was suggested that the antigenic protein 
interacts with Beta-2-Microglubulin (β2M), a component of the major 
histocompatibility complex (MHC) class I, inside the endoplasmic reticulum of the 
host cell. This prevents the β2M from interacting with its associated protein, Human 
Leukocyte Antigen-A (HLA-A), leading to partial inhibition of surface expression of 
β2M, thus reducing antigen presentation (Sreejit et al., 2014). 
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1.2.3 Region of Difference 1 
 
ESAT6 resides on a locus spanning about 9.5 kilobases in the M. tuberculosis genome 
known as the Region of Difference 1 (RD1) which has been implicated with 
mycobacterial pathogenicity. This locus contains the codes for proteins thought to be 
molecular machineries required for the ESX1 secretory system which includes 
ESAT6, CFP10, PPE and PE (Figure 1.3) (M. A. Behr, 1999; Marcel A Behr & 
Sherman, 2007; Hsu et al., 2003). 
 
This very region was found to be absent in the Bacille Calmette-Guérin (BCG) 
strain of Mycobacterium bovis which is being used as the TB vaccine (M. A. Behr, 
1999; Brodin, Rosenkrands, Andersen, Cole, & Brosch, 2004; Frota et al., 2004). The 
absence of this locus rendered them relatively harmless to humans. Within the M. 
tuberculosis complex, pathogenic species such as M. africanum, and M. bovis has been 
found to harbour the RD1 locus while the non-pathogenic species like M. microti does 
not (Marcel A Behr & Sherman, 2007). Outside of the M. tuberculosis complex, M. 
leprae, which is responsible for leprosy, and M. marinum, which causes tuberculosis-
like diseases in fish, carries homologous sequences of the M. tuberculosis ESAT6 in 
their genomes as well (Marcel A Behr & Sherman, 2007; Bekmurzayeva, Sypabekova, 
& Kanayeva, 2013; Volkman et al., 2010). 
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Figure 1.3- The RD1 locus where ESAT6 gene is located. The group of genes within 
this locus are thought to be involved in the ESX1 secretory pathway, which has a larger 
contribution towards mycobacterial pathogenicity. (Diagram adapted from Brodin et 
al., 2004)  
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Further studies on RD1 have shown that mycobacterial pathogenicity can 
indeed be affected by the presence or absence of the locus. Gao et al. in 2004 for 
instance used transposon mutagenesis to generate M. marinum strains with its RD1 
disrupted from transposon insertion, resulting in reduced cytotoxicity and cell 
spreading capabilities (Gao et al., 2004). Similarly, deletion of the RD1 locus from 
virulent M. tuberculosis strain H37Rv rendered the strain attenuated, much like the 
BCG strain (Lewis et al., 2003).  
 
Conversely, when RD1 is introduced into non-pathogenic Mycobacterium 
strains such as M. bovis BCG and M. microti, they exhibited enhanced growth and 
increased granuloma formation in infected cells and tissues (Pym, Brodin, Brosch, 
Huerre, & Cole, 2002). A similar experiment done by Guinn et al. showed that the 
introduction of functional copies of genes from the RD1 locus into attenuated mutant 
M. tuberculosis strains were able to restore their pathogenicity (Guinn et al., 2004). 
 
1.3 TB Diagnosis 
 
Based on the research findings mentioned above, it is apparent that ESAT6, contained 
within the RD1 locus, plays a central role in mycobacterial infection. This makes it a 
promising candidate for a TB diagnostic biomarker.  
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1.3.1 TB Culture as a Standard Approach to Diagnosis 
 
The Centers for Disease Control and Prevention (CDC) of the United States of 
America considers the traditional mycobacterial sputum culture as the gold standard 
for TB diagnosis (CDC, 2013a). While being more sensitive and definitive as a method 
of TB detection, it is fraught with difficulties (Konstantinos, 2010). M. tuberculosis is 
notorious for having a long doubling time and takes 2 to 6 weeks to grow (An Wang 
et al., 2014). In addition to that, Wilson et al. in 2006 reported that only 56% of culture 
of samples taken from 54 confirmed and possible TB cases came back positive 
(Wilson, Nachega, Morroni, Chaisson, & Maartens, 2006). Moreover, diagnosis by 
culture is a technically demanding approach which also necessitates a strict biosafety 
practice in the lab to prevent accidental infection to laboratory personnel 
(Bekmurzayeva et al., 2013). 
  
1.3.2 Other Common TB Screening Tests  
 
The Mantoux tuberculin skin test (TST) allows for detection of a patient’s previous 
mycobacterial infection by intracutaneous introduction of purified TB protein 
derivative (PPD) into his or her arm. A skin reaction will be observed within 2 days to 
indicate previous exposure to TB (CDC, 2013b; Kandi, 2015). The TST has the 
advantage of being a relatively simpler diagnostic test and has been used for more than 
a century ever since Felix Mendel introduced it in 1908 (Bergmann, 2014). However, 
it does not have the ability to distinguish latent from active TB and any previous 
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exposures to TB, including through BCG vaccinations and non-tuberculosis causing 
mycobacteria (NTM), will give a false positive result (Cohn et al., 2000). 
 
Another common test, known as the Acid-Fast Bacilli (AFB) smear test, could 
provide a presumptive result within a few hours. However, its sensitivity is highly 
lacking as it would need sputum samples to have a bacterial load of between 5,000 to 
10,000 bacilli per millilitre. This is in contrast to bacteria culture method which would 
only require 10 bacilli per millilitre to grow (Lawn et al., 2013; Parsons et al., 2011). 
 
1.3.3 ESAT6-Based TB Diagnostic Assay 
 
Many studies on ESAT6-focused TB diagnostic assay were done with the protein of 
interest being the antigen that then stimulates the production of interferon-γ (Munk, 
Arend, Brock, Ottenhoff, & Andersen, 2001; Pollock & Andersen, 1997; Ravn et al., 
2005; van Pinxteren et al., 2000). In other words, the diagnostic assays were 
constructed to detect the IFN-γ, and not ESAT6 itself.  
 
For direct detection of TB via the ESAT6 protein, a group comprising of 
researchers from the Zhejiang University School of Medicine, Fudan University 
School of Medicine and Nanjing Medical University reported to have successfully 
developed a new anti-ESAT6 monoclonal antibody (mAb). The group used the mAb 
in a sandwich Enzyme Linked Immunoabsorbent assay (ELISA) diagnostic assay for 
the detection of M. tuberculosis in sputum samples (Feng et al., 2011; Leng et al., 
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2014). The anti-ESAT6 mAb were reported to have 95.4% and 100% sensitivity and 
specificity respectively. However, there are several disadvantages associated with 
antibodies as mentioned in section 1.1.2. This prompts the need to develop alternative 
molecular recognition element against ESAT6.  
 
Research on using ESAT6 aptamer to screen for tuberculosis were few and far 
between. To date, only one group from Wuhan University School of Basic Medical 
Sciences have been working on the development of ESAT6 aptamer as a diagnostic 
tool (Tang et al., 2014). Another group from University of Pretoria, South Africa, have 
attempted to select an aptamer against ESAT6 but ultimately was only successful in 
getting aptamers against CFP10, the binding partner of ESAT6 (Rotherham, 
Maserumule, Dheda, Theron, & Khati, 2012). Their work on ESAT6 aptamer 
selection, use in diagnostic assays and their respective assay sensitivity and specificity 
will be discussed further in Chapter 4. 
 
The lack of studies into using ESAT6 as a biomarker for the detection of TB 
means that there are still plenty of new grounds to break and hopefully this particular 
research project will be a precursor to further development in diagnostics and 
therapeutics. 
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1.4 Objective 
 
As a class of molecules that has a cutting edge over the antibodies in many regards, 
generation of an aptamer against ESAT-6 could lead to the development of an aptamer-
based diagnostic assay of TB. Prior to its exploration as a diagnostic element, 
characterisation of the aptamer is necessary, which can provide insights into its binding 
affinity and structural elements. Thus the objectives of this study is: 
 
1. To generate RNA aptamer specific against ESAT-6 protein. 
 
2. To perform experimental and bioinformatic-based structural characterisation 
of the aptamer isolated against ESAT-6. 
a) Estimation of the binding affinity of the isolated aptamer against 
ESAT6 
b) Secondary structure determination of the aptamer 
c) Truncation of the aptamer 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
2.1 Designing Degenerate DNA library and Primers  
 
The aptamer pool and the corresponding primer pair used in this study were 
synthesised by Integrated DNA Technology (IDT, Iowa, USA). Each sequence in the 
pool were 107 nucleotides in length and consisted of two constant primer binding sites 
at either ends with a 40 nucleotides randomised region between them. The DNA library 
has the following sequence; 
5’-GGGGGAATTCTAATACGACTCACTATAGGGAGGACGATGCGG-
(N40)-CAGACGACTCGCTGAGGATCCGAGA-3’  
It is constructed using conventional solid phase phosphoramidite oligonucleotide 
synthesis. Each position of N can be occupied by either A, T, C or G nucleotide with 
a coupling efficiency of 25% each. The N40 Forward and Reverse primers’ sequences 
are underlined. The bolded nucleotides in the forward primer represents the promoter 
sequence for the T7 Polymerase enzyme. The incorporation of the T7 promoter 
sequence allows for the synthesis of single stranded RNA from double stranded DNA 
molecules after each amplification round in the SELEX cycles. ESAT-6 protein was 
purchased from Abcam (Bristol, United Kingdom). 
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2.2 PCR Amplification 
 
One µM of the N40 single stranded DNA oligonucleotide was subjected to PCR using 
BioRad MyCyler Thermal Cycler in a 100 μL of the reaction mixture comprising 1X 
PCR buffer (10 mM Tris-HCl [pH 8.8], 50 mM KCl, 0.08% [v/v] Nonidet P40), 0.2 
mM dNTP (Biotools, Madrid, Spain), 0.6 µM N40 forward and reverse primers, 
double distilled water (ddH20), 1.5 mM MgCl2 and 5 U Taq Polymerase (Thermo 
Fisher Scientific, Massachusetts, USA). The PCR protocol used is detailed as follows; 
initial denaturation at 95oC for 60 s, followed by 8-16 cycles of denaturation at 95oC 
for 30 s, annealing at 55oC for 30 s, extension at 72oC for 30 s and final extension at 
72oC for 15 min. PCR cycles were set at a minimum of 8 cycles and additional cycles 
were added if PCR product observed on gel electrophoresis. The number of PCR 
cycles were kept low where possible to minimise the accumulation of PCR artefacts 
and reduce the chances of Taq polymerase misincorporation of nucleotides The 
resulting PCR product was analysed by gel electrophoresis on a 4% agarose gel in 1X 
TAE buffer at 90 V for 20 min. The gel was later visualisation with Gel Doc™ XR+ 
Gel Documentation System (BioRad, California, USA). 
 
2.3 Ethanol Precipitation 
 
PCR products obtained in each SELEX cycles were subjected to ethanol precipitation 
before the start of the in vitro transcription reaction. The PCR product was added to 
300 µl ddH20, 40 µL 3 M pH 5.2 sodium acetate (NaOAc), and 1 mL absolute ethanol 
solution (Merck KGaA, Darmstadt, Germany). This mixture was vortexed vigorously 
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and incubated for 30 min at -80oC. Afterwards, the mixture was centrifuged at 13,000 
rpm, 4oC for 15 min using Sorvall™ ST 16R centrifuge (Thermo Fisher Scientific, 
Massachusetts, USA). The supernatant was discarded and 1 mL of 70% ethanol was 
added into the tube before being centrifuged at 13,000 rpm, 4oC for 2 min. The 
supernatant was discarded once more and the pellet was air-dried in a vacuum 
concentrator (Eppendorf, Hamburg, Germany) for 5 min. The pellet was later 
resuspended in 8 µL ddH2O. 
 
2.4 In Vitro Transcription 
 
In vitro transcription was carried out using Ampliscribe™ T7-Flash™ Transcription 
kit (Epicentre, Wisconsin, USA). The reaction mixture was set up to contain 4 µL of 
the precipitated PCR product, 1X AmpliScribe T7 reaction buffer (40 mM Tris-HCl 
[pH 7.5], 6 mM MgCl2, 10 mM NaCl, 2 mM spermidine), 7.5 mM each of ATP, CTP, 
UTP, GTP, 10 mM of dithiothreitol (DTT), 20 U of AmpliScribeTM T7 Polymerase 
Flash Enzyme Solution (10 U/µL) and 20 U of RiboGuard RNase Inhibitor (40 U/µL). 
The reaction was incubated at 37oC for 16 hours. Following that, 2 U of DNase I was 
added and the reaction was incubated for a further 20 min to remove any template 
DNA in the mixture. The reaction was later stopped with the addition of 2X RNA dye 
and it was heated at 95oC for 2 min followed by snap-cooling on ice. The in vitro 
transcription reaction mixture was later run on a denaturing urea-PAGE and was 
purified via rapid crush-and-soak method. 
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2.5 Denaturing Urea-PAGE 
 
The 10% 7 M denaturing urea PAGE gel was prepared with 1X TBE, 10% 
Acrylamide/Bis-acrylamide solution (BioRad, California, USA), 7 M urea (Merck 
KGaA, Darmstadt, Germany), ddH2O, 0.1% TEMED (BioRad, California, USA) and 
1% APS in a BioRad Mini Protean Tetra Cell system (BioRad, California, USA). 
Electrophoresis was carried out using BioRad Mini-PROTEAN 3 Electrophoresis Cell 
(Bio-Rad Laboratories, Hercules, USA) in 1X TBE buffer at 140 V for 60 min. 
 
2.6 Rapid Crush-and-Soak-based RNA Purification 
 
The in vitro transcribed RNA was purified by rapid crush and soak method which was 
adapted from the technique outlined by Citartan et al. (Citartan, Tan, & Tang, 2012). 
Upon the completion of the electrophoresis and the removal of the glass plates, the gel 
was then wrapped with saran wrap and placed on a silica coated plate. The location of 
the RNA on the gel was detected by UV shadowing. The gel was shone with a hand 
held short wave (254 nm) UVGL-58 UV lamp (UVP, California, USA) in a dark room 
and the image produced was marked. The marked area of the gel was cut and 
transferred to a new centrifuge tube for it to be crushed with a pipette tip. Four hundred 
microliters of ddH20 was added to it and the tube was then incubated at 50
oC for 30 
min. Afterwards, 1 mL of absolute ethanol was added into the tube. The mixture was 
shaken vigorously and centrifuged at 15,000 rpm for 2 min. The supernatant was 
transferred to a new tube and added with 40 µl sodium acetate. The tube was incubated 
for 30 min at -80oC. The subsequent ethanol precipitation steps followed as described 
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in section 2.3. The pellet was then resuspended in ddH20 and the resulting RNA 
concentration was determined using a NanoPhotometer P300 (Implen GmbH, Munich, 
Germany). Following quantification, an appropriate amount of RNA was used for each 
cycle of SELEX. 
 
2.7 SELEX Cycles 
 
In this study, each SELEX cycle carried out consisted of an iterative process of 
incubation of the nucleic acid pool and the target (2.7.1), partitioning to separate the 
target-bound and unbound nucleic acid molecules (2.7.2), elution of the target-bound 
nucleic acid molecules (2.7.3), amplification (2.7.4), counter selection (2.7.5) and 
sequence analysis (2.8) 
 
2.7.1 Incubation of Nucleic Acid Pool and Target 
 
For the 1st cycle of SELEX, the reaction mixture was set up to contain 9.5 µM of the 
initial nucleic acid pool, 20 µM of the ESAT6 protein, 100 µM yeast tRNA (Invitrogen 
Corporation, Carlsbad, USA) in 1X SELEX binding buffer (10 mM HEPES-KOH [pH 
7.4], 150 mM NaCl) (GE Healthcare Life Sciences, Buckinghamshire, UK). Prior to 
the addition of the target protein and yeast tRNA, the mixture was heated at 95oC 
followed by cooling at room temperature for 5 min. After protein and yeast tRNA has 
been added, the reaction was incubated at room temperature for 15 min.  
 
